3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia
2
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Lymphoma
1
Lichen Planus, Oral
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Erectile Dysfunction
1
Anemia
1
Interventions
Sildenafil Citrate
8
Tadalafil
2
Surveys and Questionnaires
2
Alprostadil
2
udenafil
1
trametinib
1
sotorasib
1
selpercatinib
1
pembrolizumab
1
osimertinib
1
mirabegron
1
methyl 3-mercaptopropionimidate
1
lorlatinib
1
dabrafenib
1
cemiplimab
1
brigatinib
1
bicalutamide
1
alpha-Tocopherol
1
alectinib
1
Vitamin E
1
Tamoxifen
1
Surgical Instruments
1
Saline Solution
1
Restraint, Physical
1
Psychiatric Rehabilitation
1
Preservation, Biological
1
Pentoxifylline
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Erectile Dysfunction
×
Erythropoietin
×
Clear all
NCT00737893
2021-04-08
ERECT
Johns Hopkins University
Phase 2
Completed
56 enrolled
27 charts